
The study of the CANVAS Program examined type III collagen (COL III) turnover in participants with type 2 diabetes. Higher baseline levels of PRO-C3 and C3M were linked to increased cardiovascular risks. Canagliflozin treatment decreased PRO-C3 levels and increased CTX-III levels, indicating shifts in COL III turnover dynamics. These biomarkers are potential tools for monitoring the tissue remodeling effects of canagliflozin and similar treatments.
Like
Save
Share